Methylselenocysteine – a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs

Bibliography

• Jemal A, Siegel R, Ward E, Cancer statistics, 2009. CA Cancer J Clin 2009;8(4):225-49
   Google Scholar
• Savage P, Stebbing J, Bower M, Why does cytotoxic chemotherapy cure only some cancers? Nat Clin Pract Oncol 2009;6(1):43-52
   PubMedGoogle Scholar
• Rustum YM, Toth K, Seshadri M, Architectural heterogeneity in tumors caused by differentiation alters intratumoral drug distribution and affects therapeutic synergy of antiangiogenic organoselenium compound. J Oncol 2010;2010:396286
   PubMedGoogle Scholar
• Bhattacharya A, Toth K, Mazurchuk R, Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clin Cancer Res 2004;10(23):8005-17
   PubMed Web of Science ®Google Scholar
• Jackson MI, Combs GF Jr. Selenium and anticarcinogenesis: underlying mechanisms. Curr Opin Clin Nutr Metab Care 2008;11(6):718-26
   PubMed Web of Science ®Google Scholar
• Shamberger RJ, Frost DV. Possible protective effect of selenium against human cancer. Can Med Assoc J 1969;100(14):682
   PubMed Web of Science ®Google Scholar
• Lippman SM, Klein EA, Goodman PJ, Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301(1):39-51
   PubMed Web of Science ®Google Scholar
• Fakih MG, Pendyala L, Brady W, A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. Cancer Chemother Pharmacol 2008;62(3):499-508
   PubMed Web of Science ®Google Scholar
• Azrak RG, Cao S, Pendyala L, Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. Biochem Pharmacol 2007;73(9):1280-7
   PubMed Web of Science ®Google Scholar
• Cao S, Durrani FA, Rustum YM. Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts. Clin Cancer Res 2004;10(7):2561-9
   PubMed Web of Science ®Google Scholar
• Fakih M, Cao S, Durrani FA, Rustum YM. Selenium protects against toxicity induced by anticancer drugs and augments antitumor activity: a highly selective, new, and novel approach for the treatment of solid tumors. Clin Colorectal Cancer 2005;5(2):132-5
   PubMedGoogle Scholar
• Bhattacharya A, Seshadri M, Oven SD, Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads to therapeutic synergy with anticancer drugs. Clin Cancer Res 2008;14(12):3926-32
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Toth K, Sen A, Inhibition of colon cancer growth by methylselenocysteine-induced angiogenic chemomodulation is influenced by histologic characteristics of the tumor. Clin Colorectal Cancer 2009;8(3):155-62
   PubMed Web of Science ®Google Scholar
• Tredan O, Galmarini CM, Patel K, Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007;99(19):1441-54
   PubMed Web of Science ®Google Scholar
• Marusyk A, Polyak K. Tumor heterogeneity: causes and consequences. Biochim Biophys Acta 2010;1805(1):105-17
   PubMed Web of Science ®Google Scholar
• Rustum Y, Pendyala L, Creaven P, A phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose Irinotecan in patients with solid tumors. ASCO annual meeting proceedings. J Clin Oncol 2007;25(18S):2574
   Google Scholar
• Jain RK. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev 2001;46(1-3):149-68
   PubMed Web of Science ®Google Scholar
• Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 2003;8(9):396-403
   PubMed Web of Science ®Google Scholar
• Mollica F, Jain RK, Netti PA. A model for temporal heterogeneities of tumor blood flow. Microvasc Res 2003;65(1):56-60
   PubMed Web of Science ®Google Scholar
• Peterson HI. Modification of tumour blood flow–a review. Int J Radiat Biol 1991;60(1-2):201-10
   PubMed Web of Science ®Google Scholar
• Bhattacharya A, Toth K, Durrani FA, Hypoxia specific drug tirapazamine does not abrogate hypoxic cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma A253 xenografts. Neoplasia 2008;10(8):857-65
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ, Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25(12):1539-44
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50
   PubMed Web of Science ®Google Scholar
• Kabbinavar F, Hurwitz HI, Fehrenbacher L, Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5
   PubMed Web of Science ®Google Scholar
• Miller K, Wang M, Gralow J, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357(26):2666-76
   PubMed Web of Science ®Google Scholar
• Kohne C, Bajetta E, Lin E, Final results of CONFIRM 2: a multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo. J Clin Oncol 2007;25(18S): ASCO Ann Meet Proc. Part I; 4033
   PubMedGoogle Scholar
• Scagliotti G, Novello S, von Pawel J, Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28(11):1835-42
   PubMed Web of Science ®Google Scholar
• Ma J, Waxman DJ. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther 2008;7(12):3670-84
   PubMed Web of Science ®Google Scholar
• Jain RK, Duda DG, Clark JW, Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40
   PubMedGoogle Scholar
• Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007;7(6):475-85
   PubMed Web of Science ®Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96(12):1788-95
   PubMed Web of Science ®Google Scholar
• de Groot JF, Fuller G, Kumar AJ, Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12(3):233-42
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J, Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15(3):220-31
   PubMed Web of Science ®Google Scholar
• Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev 2008;8(8):592-603
   Google Scholar
• Folkins C, Man S, Xu P, Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007;67(8):3560-4
   PubMed Web of Science ®Google Scholar
• Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
   PubMed Web of Science ®Google Scholar
• Mancuso MR, Davis R, Norberg SM, Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 2006;116(10):2610-21
   PubMed Web of Science ®Google Scholar
• Shaked Y, Ciarrocchi A, Franco M, Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313(5794):1785-7
   PubMed Web of Science ®Google Scholar
• Gerhardt H, Semb H. Pericytes: gatekeepers in tumour cell metastasis? J Mol Med 2008;86(2):135-44
   PubMed Web of Science ®Google Scholar
• Stoeltzing O, Ahmad SA, Liu W, Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. Cancer Res 2003;63(12):3370-7
   PubMed Web of Science ®Google Scholar
• Ceradini DJ, Kulkarni AR, Callaghan MJ, Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004;10(8):858-64
   PubMed Web of Science ®Google Scholar
• De Falco E, Porcelli D, Torella AR, SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004;104(12):3472-82
   PubMed Web of Science ®Google Scholar
• Manalo DJ, Rowan A, Lavoie T, Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005;105(2):659-69
   PubMed Web of Science ®Google Scholar
• Sun M, Lughezzani G, Perrotte P, Treatment of metastatic renal cell carcinoma. Nat Rev Urol 2010;7(6):327-38
   PubMed Web of Science ®Google Scholar
• Hubbard J, Grothey A. Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol 2010;22(4):374-80
   PubMed Web of Science ®Google Scholar
• Zhu X, Wu S, Dahut WL, Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007;49(2):186-93
   PubMed Web of Science ®Google Scholar
• Frangie C, Lefaucheur C, Medioni J, Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma. Lancet Oncol 2007;8(2):177-8
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006;33(5 Suppl 10):S26-34
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-91
   PubMed Web of Science ®Google Scholar
• Widakowich C, de Castro G Jr, de Azambuja E, Review: side effects of approved molecular targeted therapies in solid cancers. Oncologist 2007;12(12):1443-55
   PubMed Web of Science ®Google Scholar
• van Heeckeren WJ, Sanborn SL, Narayan A, Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Curr Opin Hematol 2007;14(5):468-80
   PubMed Web of Science ®Google Scholar
• Zangari M, Fink LM, Elice F, Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009;27(29):4865-73
   PubMed Web of Science ®Google Scholar
• Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. Am J Med 2009;122(4):322-8
   PubMed Web of Science ®Google Scholar
• Clark LC, Combs GF Jr, Turnbull BW, Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional prevention of cancer study group. JAMA 1996;276(24):1957-63
   PubMed Web of Science ®Google Scholar
• Shamberger RJ, Willis CE. Selenium distribution and human cancer mortality. Crit Rev Clin Lab Sci 1971;2(2):211-21
   Google Scholar
• Zeng H, Combs GF Jr. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem 2008;19(1):1-7
   PubMed Web of Science ®Google Scholar
• Lu J, Jiang C, Kaeck M, Dissociation of the genotoxic and growth inhibitory effects of selenium. Biochem Pharmacol 1995;50(2):213-19
   PubMed Web of Science ®Google Scholar
• Lu J, Kaeck M, Jiang C, Selenite induction of DNA strand breaks and apoptosis in mouse leukemic L1210 cells. Biochem Pharmacol 1994;47(9):1531-5
   PubMed Web of Science ®Google Scholar
• Wilson AC, Thompson HJ, Schedin PJ, Effect of methylated forms of selenium on cell viability and the induction of DNA strand breakage. Biochem Pharmacol 1992;43(5):1137-41
   PubMed Web of Science ®Google Scholar
• Kaeck M, Lu J, Strange R, Differential induction of growth arrest inducible genes by selenium compounds. Biochem Pharmacol 1997;53(7):921-6
   PubMed Web of Science ®Google Scholar
• Ip C, Hayes C, Budnick RM, Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 1991;51(2):595-600
   PubMed Web of Science ®Google Scholar
• Ganther HE. Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase. Carcinogenesis 1999;20(9):1657-66
   PubMed Web of Science ®Google Scholar
• Sinha R, Said TK, Medina D. Organic and inorganic selenium compounds inhibit mouse mammary cell growth in vitro by different cellular pathways. Cancer Lett 1996;107(2):277-84
   PubMed Web of Science ®Google Scholar
• Xiao H, Parkin KL. Induction of phase II enzyme activity by various selenium compounds. Nutr Cancer 2006;55(2):210-23
   PubMed Web of Science ®Google Scholar
• El-Bayoumy K, Sinha R. Molecular chemoprevention by selenium: a genomic approach. Mutat Res 2005;591(1-2):224-36
   PubMed Web of Science ®Google Scholar
• Combs GF Jr, Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998;79(3):179-92
   PubMed Web of Science ®Google Scholar
• Gupta A, Miki K, Xu M, Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine. Anticancer Res 2003;23(2B):1181-8
   PubMed Web of Science ®Google Scholar
• Miki K, Xu M, Gupta A, Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res 2001;61(18):6805-10
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Gupta A, Xu M, Methioninase gene therapy with selenomethionine induces apoptosis in bcl-2-overproducing lung cancer cells. Cancer Gene Ther 2003;10(6):445-50
   PubMed Web of Science ®Google Scholar
• Bogye G, Alfthan G, Machay T. Bioavailability of enteral yeast-selenium in preterm infants. Biol Trace Elem Res 1998;65(2):143-51
   PubMed Web of Science ®Google Scholar
• Thomson CD, Robinson MF, Butler JA, Long-term supplementation with selenate and selenomethionine: selenium and glutathione peroxidase (EC 1.11.1.9) in blood components of New Zealand women. Br J Nutr 1993;69(2):577-88
   PubMed Web of Science ®Google Scholar
• Gladyshev VN, Hatfield DL. Selenocysteine-containing proteins in mammals. J Biomed Sci 1999;6(3):151-60
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Ogra Y, Ishiwata K, Selenosugars are key and urinary metabolites for selenium excretion within the required to low-toxic range. Proc Natl Acad Sci USA 2002;99(25):15932-6
   PubMed Web of Science ®Google Scholar
• Wang Z, Jiang C, Lu J. Induction of caspase-mediated apoptosis and cell-cycle G1 arrest by selenium metabolite methylselenol. Mol Carcinog 2002;34(3):113-20
   PubMed Web of Science ®Google Scholar
• Ip C, Ganther H. Efficacy of trimethylselenonium versus selenite in cancer chemoprevention and its modulation by arsenite. Carcinogenesis 1988;9(8):1481-4
   PubMed Web of Science ®Google Scholar
• Ip C, Ganther H. Biological activities of trimethylselenonium as influenced by arsenite. J Inorg Biochem 1992;46(3):215-22
   PubMed Web of Science ®Google Scholar
• Jacobs M, Forst C. Toxicological effects of sodium selenite in Swiss mice. J Toxicol Environ Health 1981;8(4):587-98
   PubMed Web of Science ®Google Scholar
• Jacobs M, Forst C. Toxicological effects of sodium selenite in Sprague-Dawley rats. J Toxicol Environ Health 1981;8(4):575-85
   PubMed Web of Science ®Google Scholar
• Corcoran NM, Hovens CM, Michael M, Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. Br J Cancer 2010;103(4):462-8
   PubMed Web of Science ®Google Scholar
• Lu J, Berndt C, Holmgren A. Metabolism of selenium compounds catalyzed by the mammalian selenoprotein thioredoxin reductase. Biochim Biophys Acta 2009;1790(11):1513-19
   PubMed Web of Science ®Google Scholar
• Foster SJ, Kraus RJ, Ganther HE. The metabolism of selenomethionine, Se-methylselenocysteine, their selenonium derivatives, and trimethylselenonium in the rat. Arch Biochem Biophys 1986;251(1):77-86
   PubMed Web of Science ®Google Scholar
• Li GX, Lee HJ, Wang Z, Superior in vivo inhibitory efficacy of methylseleninic acid against human prostate cancer over selenomethionine or selenite. Carcinogenesis 2008;29(5):1005-12
   PubMed Web of Science ®Google Scholar
• Abdulah R, Miyazaki K, Nakazawa M, Chemical forms of selenium for cancer prevention. J Trace Elem Med Biol 2005;19(2-3):141-50
   PubMed Web of Science ®Google Scholar
• Foster SJ, Kraus RJ, Ganther HE. Formation of dimethyl selenide and trimethylselenonium from selenobetaine in the rat. Arch Biochem Biophys 1986;247(1):12-19
   PubMed Web of Science ®Google Scholar
• Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998;128(11):1845-54
   PubMed Web of Science ®Google Scholar
• Ip C, Thompson HJ, Zhu Z, In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60(11):2882-6
   PubMed Web of Science ®Google Scholar
• Spallholz JE, Hoffman DJ. Selenium toxicity: cause and effects in aquatic birds. Aquat Toxicol 2002;57(1-2):27-37
   PubMed Web of Science ®Google Scholar
• Demirel-Yilmaz E, Dincer D, Yilmaz G, The effect of selenium and vitamin E on microvascular permeability of rat organs. Biol Trace Elem Res 1998;64(1-3):161-8
   PubMed Web of Science ®Google Scholar
• Jiang C, Jiang W, Ip C, Selenium-induced inhibition of angiogenesis in mammary cancer at chemopreventive levels of intake. Mol Carcinog 1999;26(4):213-25
   PubMed Web of Science ®Google Scholar
• Jiang C, Ganther H, Lu J. Monomethyl selenium-specific inhibition of MMP-2 and VEGF expression: implications for angiogenic switch regulation. Mol Carcinog 2000;29(4):236-50
   PubMed Web of Science ®Google Scholar
• Hwang JT, Kim YM, Surh YJ, Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells. Cancer Res 2006;66(20):10057-63
   PubMed Web of Science ®Google Scholar
• Yin MB, Li ZR, Toth K, Potentiation of irinotecan sensitivity by Se-methylselenocysteine in an in vivo tumor model is associated with downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia-inducible factor 1alpha expression, resulting in reduced angiogenesis. Oncogene 2006;25(17):2509-19
   PubMed Web of Science ®Google Scholar
• Ambs S, Merriam WG, Ogunfusika MO, p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nat Med 1998;4(12):1371-6
   PubMed Web of Science ®Google Scholar
• Gallo O, Masini E, Morbidelli L, Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998;90(8):587-96
   PubMed Web of Science ®Google Scholar
• Caffrey PB, Frenkel GD. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother Pharmacol 2000;46(1):74-8
   PubMed Web of Science ®Google Scholar
• Sieja K. Protective role of selenium against the toxicity of multi-drug chemotherapy in patients with ovarian cancer. Pharmazie 2000;55(12):958-9
   PubMed Web of Science ®Google Scholar
• Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy. Gynecol Oncol 2004;93(2):320-7
   PubMed Web of Science ®Google Scholar
• Hu YJ, Chen Y, Zhang YQ, The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res 1997;56(3):331-41
   PubMed Web of Science ®Google Scholar
• Weijl NI, Elsendoorn TJ, Lentjes EG, Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer 2004;40(11):1713-23
   PubMed Web of Science ®Google Scholar
• Ohkawa K, Tsukada Y, Dohzono H, The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity. Br J Cancer 1988;58(1):38-41
   PubMed Web of Science ®Google Scholar
• Fischer JL, Mihelc EM, Pollok KE, Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther 2007;6(1):355-61
   PubMed Web of Science ®Google Scholar
• Chintala S, Toth K, Cao S, Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha. Cancer Chemother Pharmacol 2010;66(5):899-911
   PubMed Web of Science ®Google Scholar
• El-Bayoumy K. The negative results of the SELECT study do not necessarily discredit the selenium-cancer prevention hypothesis. Nutr Cancer 2009;61(3):285-6
   PubMed Web of Science ®Google Scholar